SEC Filing Summary: Regeneron Pharmaceuticals, Inc. (13F-HR)
Business Context and Reporting Period
This filing is a Form 13F-HR submitted by Regeneron Pharmaceuticals, Inc., an institutional investment manager, for the quarter ended June 30, 2026. The report was signed by Leonard Brooks, Senior Vice President and Treasurer, on August 7, 2026. This form discloses the equity securities held by the manager at the end of the reporting period.
Key Financial Metrics
As a 13F-HR filing, this document reports portfolio holdings rather than the company's operational financial performance (e.g., revenue, profit, or cash flow). The filing provides the following aggregate data regarding the reported holdings:
- Total Value of Reported Holdings: $177,219,142
- Number of Securities Reported: 3
- Number of Other Included Managers: 0
Note: The filing text does not provide clear values for Regeneron Pharmaceuticals' own revenue, profit, margins, debt, or liquidity, as this form is designed to disclose investment positions, not corporate financial statements.
Material Changes
The filing text does not provide comparative data for the prior period (e.g., March 31, 2026) to determine material changes in holdings or value. Consequently, no analysis of changes versus the prior comparable period can be derived from this document alone.
Guidance, Outlook, and Risks
This form does not contain management commentary, forward-looking guidance, risk factors, or contingencies related to Regeneron Pharmaceuticals' business operations. It strictly lists the securities held by the reporting manager.
Key Facts for Investor Verification
- Verify the specific titles and quantities of the 3 securities held to understand the composition of the $177.2 million portfolio.
- Confirm whether this report represents all holdings of the manager or if other managers report additional holdings (the filing states "NONE" for other included managers).
- Recognize that this document does not reflect Regeneron Pharmaceuticals' internal financial health; refer to Form 10-Q or 10-K for operational metrics.